Dexamethasone controlled-release implant - pSivida

Drug Profile

Dexamethasone controlled-release implant - pSivida

Alternative Names: Dexamethasone sustained-release - pSivida

Latest Information Update: 16 Nov 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator pSivida
  • Developer Hospital for Special Surgery; pSivida
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Corticosteroids; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Osteoarthritis

Most Recent Events

  • 16 Nov 2016 Chemical structure information added
  • 01 Aug 2016 Phase-I trials in Osteoarthritis in USA (Implant) (9215847; 9206473)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top